Edento Ltd Secures Pre-Seed Funding Days After Incorporation

London based Edento Ltd has completed a pre-seed funding round just days after its incorporation. Directed by Alexander Raychuk, the founder of the healthcare networking platform Medentee, the new venture focuses on software development and management consultancy within the professional, scientific, and technical sectors.

Incorporated on March 10, 2026, Edento is a fresh addition to the UK tech ecosystem. Because the company is in its absolute infancy, it has not yet reported revenue, employee headcounts, or profit and loss metrics. However, its foundation heavily leverages Raychuk's extensive experience in clinical technology, business development, and digital networking. Through his previous venture, Medentee, Raychuk built a comprehensive platform that connects the dental and broader healthcare ecosystem, facilitating event driven collaboration, secure data storage, and professional community building. Edento is positioned to build on this deep industry expertise. The company aims to provide specialized software solutions and specialized sales agency services tailored to scientific and technical professionals, addressing the ongoing need for bespoke digital infrastructure and strategic management in highly specialized, regulated industries.

The pre-seed round was allotted on March 10, 2026, which coincides exactly with the company's date of incorporation, and the paperwork was officially filed on March 13, 2026. Exact financial details regarding the round size, the company valuation, and the names of specific investors remain undisclosed in these initial filings. As this is the first capital injection for the newly formed entity, there are no previous funding rounds for comparison. The rapid succession of incorporation and funding allotment strongly suggests prearranged early backing, a common occurrence when a founder has an established track record and an existing network of industry investors.

This development fits neatly into the current UK funding landscape for early stage B2B software and health tech. The market remains highly competitive but exceptionally receptive to proven founders. Pre-seed rounds in London typically range from £250k to £1m, depending heavily on the founder's history and the immediate market potential of the technology. With Raychuk's proven background in the healthcare networking space, Edento is well positioned to attract continued interest from early stage venture capital firms that focus on specialized technical and scientific software solutions. Despite a broader venture capital market correction over the last two years, seed stage investments in the UK have shown remarkable resilience. Investors continue to deploy capital into ventures led by experienced entrepreneurs who deeply understand the operational nuances of professional and scientific sectors.